Clinical Trial Phases (1, 2, 3) Explained
Three phases. Three completely different questions. Three completely different success rates. Here's what investors need to know.
Start free with Clinical Investor â"The drug passed Phase 2" sounds great until you realize it's still 4-6 years from approval and a 31% chance of even reaching Phase 3 success. Each phase tests different things and has dramatically different base rates of success. Here's the breakdown.
Phase 1: Safety and dosing
- Question: Is the drug safe in humans? What's the right dose?
- Population: 20-80 patients (or healthy volunteers for non-cancer drugs)
- Duration: 6-18 months
- Success rate: ~63% advance to Phase 2
- What positive Phase 1 means: The drug doesn't kill people at therapeutic doses. Useful but limited â most drugs pass Phase 1.
- Investor implications: Phase 1 readouts move stock prices ~10-30%. Less impactful than later phases unless safety signal is unexpectedly clean (driving Phase 2 confidence).
Phase 2: Preliminary efficacy + dose finding
- Question: Does the drug work? What's the optimal dose for Phase 3?
- Population: 100-300 patients with the target disease
- Duration: 1-3 years
- Success rate: ~31% advance to Phase 3 (THE hardest gate)
- What positive Phase 2 means: The drug shows activity in the target population. The bar for "positive" can vary; pay attention to whether the trial was POWERED to detect efficacy or just exploratory.
- Investor implications: Phase 2 readouts often move stocks 50-150%. The most asymmetric readouts in biotech.
Phase 3: Pivotal trials for FDA approval
- Question: Does the drug work in a large, diverse population? Better than placebo or standard-of-care?
- Population: 300-3000+ patients
- Duration: 2-6 years
- Success rate: ~58% lead to FDA approval (varies by indication)
- What positive Phase 3 means: Strong evidence the drug works at scale; usually sufficient for FDA filing. Companies often file an NDA within 6 months of positive Phase 3.
- Investor implications: Stock moves vary 30-100% on Phase 3 readouts. Less variance than Phase 2 because the company's value has already been re-rated based on Phase 2 data.
Phase 4: Post-approval studies
- Question: Long-term safety, real-world effectiveness, additional indications
- Population: Large; often required by FDA as a condition of approval
- Investor implications: Mostly informational; rarely market-moving unless a safety signal emerges that triggers a label change or withdrawal.
Get the catalyst calendar + Trial Translator
Free tier: weekly catalyst briefing, basic company profiles. Premium ($19/mo): real-time alerts, unlimited Trial Translator, deep dives.
Start free âFrequently Asked Questions
- What's the difference between Phase 2a and Phase 2b?
- Phase 2a is exploratory (smaller, dose-finding). Phase 2b is more confirmatory (larger, statistically powered). Phase 2b is closer to a "mini Phase 3" and is often the basis for partnership/licensing decisions.
- Can a drug skip Phase 3?
- Sometimes â for breakthrough therapies in rare diseases or unmet medical need, the FDA can accept Phase 2 data for "accelerated approval" with a Phase 4 confirmatory trial. Common in oncology and rare disease.
- What's the failure rate from drug discovery to approval?
- Roughly 90% of drugs that enter Phase 1 never reach approval. Most failures occur in Phase 2 (efficacy) and Phase 3 (failing to confirm Phase 2 results in larger populations).
- Why do Phase 2 trials fail at higher rates than Phase 3?
- Phase 2 has tighter inclusion criteria and more responsive populations. Phase 3 includes more "real-world" patients with comorbidities and concomitant medications. Effect sizes often shrink in Phase 3.
Related guides
Educational only. Not investment advice. Biotech investing carries substantial risk; consult a licensed advisor.